Summary: CD4 + CD25 + T-regulatory cells (T reg ) can inhibit the proliferation and cytokine secretion of CD4 + CD25 À helper T cells in mice and humans. In murine tumor models, the presence of these T reg cells can inhibit the antitumor effectiveness of T-cell transfer and active immunization approaches. We have thus initiated efforts to eliminate T reg cells selectively from human peripheral blood mononuclear cells (PBMCs) to potentially bolster antitumor responses. LMB-2 is a recombinant immunotoxin that is a fusion of a single-chain Fv fragment of the antiTac anti-CD25 monoclonal antibody to a truncated form of the bacterial Pseudomonas exotoxin A. In vitro incubation of human PBMCs with LMB-2 reduced the levels of CD4 + CD25 + and Foxp3-expressing cells without impairing the function of the remaining lymphocytes. The short in vivo half-life of LMB-2 makes it an attractive candidate for reducing human T reg cells in vivo before the administration of cancer vaccine or cell transfer immunotherapy approaches.
I
n humans, naturally occurring CD4 + CD25 + Tregulatory (T reg ) cells, which represent approximately 5% of the peripheral CD4 + T-cell compartment, maintain homeostatic peripheral self-tolerance by suppressing autoreactive T cells. 1 T reg cells constitutively express the a-chain of the interleukin (IL)-2 receptor (CD25), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor (GITR), and transcription factor Forkhead box P3 (Foxp3). 2 Compared with CD25 À CD4 + T cells, CD25 + T reg cells exhibit a hypoproliferative capacity and possess the ability to suppress CD8 + and CD25 À CD4 + T-cell activation in vitro through a largely unknown mecha nism. That T reg cells are key mediators of self-tolerance is evidenced in individuals genetically predisposed to the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), a recessive and often fatal disorder of early childhood caused by loss of function mutations of Foxp3 and the resultant lack of T reg cells. 3 Peripheral blood lymphocytes from melanoma patients contain functional CD4 + CD25 + T reg cells, and melanoma antigen-specific T reg cells have been described. 4, 5 Further, CD4 + CD25 + T reg cells in human metastatic melanoma lymph nodes have been reported to inhibit the function of infiltrating T cells. 6 T reg cells are also reported to contribute to growth of human ovarian carcinomas in vivo by suppressing tumor-specific T-cell immunity and to be associated with reduced survival of patients with ovarian cancer. 7 Thus, the immune inhibitory effects of T reg cells may account, in part, for the poor clinical response rates reported in cancer patients receiving immunotherapy. The impact of CD4 + CD25 + T reg cells on adoptive immunotherapy has recently been evaluated in a mouse melanoma model. Adoptive transfer of tumor/self-reactive CD8 + T cells with vaccination and IL-2 led to regression of large established B16 melanoma in lymphodepleted hosts. 8 In cotransfer experiments, adoptive transfer of CD25 À CD4 + T helper cells with tumor/self-reactive CD8 + T cells and vaccination into CD4 + T-cell-deficient recipients resulted in regression of established tumor and concomitant autoimmunity. 9 In contrast, cotransfer of CD25 + T reg cells alone or combined with CD25 À CD4 + T helper cells inhibited effective immunotherapy. Based on preclinical findings suggesting that selective depletion of T reg cells and enrichment of CD4 + T helper cells may improve cancer therapy, we sought to neutralize the suppressive effects of T reg cells to bolster antitumor immune responses.
Immunotoxins, which couple the specificity of monoclonal antibodies (mAbs) with a highly lethal cellular toxin, have been used to selectively eliminate cell subpopulations in vivo. 10 LMB-2 [anti-Tac(Fv)-PE38] is a single-chain Fv fragment of the anti-CD25 mAb (Daclizumab [ZENAPAX]) fused to a truncated form of the bacterial toxin Pseudomonas exotoxin (PE). complete tumor regression. 13 Similarly, in phase I trials, LMB-2 administration induced clinical responses in patients with CD25 + hematologic malignancies, including cutaneous T-cell lymphoma, hairy cell leukemia, chronic lymphocytic leukemia, Hodgkin disease, and adult T-cell leukemia. 14, 15 In the current study, LMB-2 was evaluated for the ability to eliminate CD25 + T reg cells selectively from peripheral blood mononuclear cells (PBMCs) in vitro. Here, we demonstrate that treatment of human PBMCs with a recombinant immunotoxin, LMB-2, can specifically target and diminish CD25 + T reg cells in vitro without jeopardizing the functional and proliferative potentials of the remaining effector T-cell precursors.
MATERIALS AND METHODS

Patient Samples
PBMCs were isolated by Ficoll-Hypaque separation from normal donors after obtaining informed consent and were used fresh or were cryopreserved at 10 8 cells per vial in heat-inactivated human antibody serum with 10% dimethyl sulfoxide and stored at À 1801C. 
Media
PBMCs were cultured in complete media (CM) consisting of RPMI 1640 (Invitrogen Corporation, Carlsbad, CA) supplemented with 2 mM glutamine (Biofluids, Rockville, MD), 25 mM HEPES buffer (Biofluids), 100 U/mL penicillin (Biofluids), 100 mg/mL streptomycin (Biofluids), and 20% heat-inactivated fetal bovine serum (Gemini Bioproducts, Woodland, CA).
Flow Cytometry
Flow cytometry was used to assess the surface expression of selected T-cell markers and was performed as previously described. 17 
In Vitro Sensitization
The 10-day in vitro sensitization was carried out as previously described. 18 Briefly, after 48 hours of exposure to LMB-2, PBMCs were washed and plated at 3 Â 10 6 per well in 24-well plates with 1 mM soluble peptide (Flu 58-66 GILGFVFTL or gp100 280-288(288V) YLEPGPVTV) for 10 days. Cells were harvested, washed, and plated in 96-well plates with T2 cells alone or pulsed with peptide at 1 mM. After 24 hours, the supernatant from each well was harvested and interferon-g (IFNg) was measured using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Pierce Endogen, Rockford, IL).
Real-Time Polymerase Chain Reaction
Levels of messenger RNA (mRNA) Foxp3 were analyzed using the quantitative real-time polymerase chain reaction (PCR) with the TaqMan Gene Expression Assay (Applied Biosystems, Foster City, CA) as described previously. 19 In each experiment, 500 ng total RNA was isolated from CD4-purified lymphocytes using the RNeasy Mini Kit (Qiagen USA, Valencia, CA) and reverse-transcribed to prepare complementary DNA (cDNA) using the ThermoScript reverse transcriptase (RT)-PCR system (Invitrogen) according to the manufacturer's instructions. The TaqMan Universal Master Mix (Applied Biosystems) was also used as a template. For b-actin, the forward primer used was 5 0 -GCGA-GAAGATGACCCAGATC-3 0 , the reverse primer used was 5 0 -CCAGTAGGTACGGCCAGAGG-3 0 , and the probe used was 5 0 -FAM-CCAGCCATGTACGTTGC-TATCCAGGC-TAMRA-3 0 . For Foxp3, the combined primer, probe reagent was used (Assay-on-demand gene expression assay, Applied Biosystems). The ABI Prism 7700 detection system (Applied Biosystems) was used with the following settings: 501C for 2 minutes, followed by 951C for 10 minutes, followed by 40 cycles of 951C for 15 seconds and 601C for 1 minute.
Lymphocyte Separation
CD4
+ cells were separated from whole PBMCs by magnetic bead selection using the Dynal CD4 negative isolation kit (Dynal Biotech; Invitrogen) according to the manufacturer's instructions. In indicated experiments, CD4 + T cells were enriched using the Dynal CD4 positive isolation kit (Dynal Biotech; Invitrogen). For suppression assays, CD4 + cells were further purified into CD25 À and CD25 + fractions using the Dynal T reg kit according to the manufacturer's instructions. Separations were performed in phosphate-buffered saline (PBS) with 0.1% bovine serum albumin.
Proliferation Assay
PBMCs treated with 0 or 100 ng/mL LMB-2 for 48 hours were plated in 96-well plates coated with anti-CD3 (1 mg/mL) at a cell concentration of 50 Â 10 3 PBMCs per well. On days 2 and 4 of cell culture, 1 mCi [ 3 H]-thymidine incorporation was added per well and further cultured for 18 hours before harvesting for measurement on days 3 and 5. Plates were harvested onto nylon filters using the Betaplate system, and radioactivity was quantified using a Betaplate counter. Results are expressed as the mean counts per minute of 24 cultures ± standard error of measure (SEM) per condition.
RESULTS
Impact of LMB-2 on Resting Lymphocytes
Doses of LMB-2 ranging from a final concentration of 0 to 1000 ng/mL were incubated in vitro with resting PBMCs for 48 hours. The surface expression of CD25 on CD3 + CD4 + lymphocytes within this population decreased by 75% to 90% (Fig. 1A) , which was paralleled by the decrease in Foxp3 expression (see Fig. 1B ). Resting PBMCs were sensitive to LMB-2 at 1 ng/mL, but a maximum impact was observed between 100 and 1000 ng/mL. This experiment was representative of several dose titrations performed. For the remainder of our in vitro experiments, 100 ng/mL was chosen as the treatment dose.
To determine the optimal exposure time, PBMCs were harvested at 12, 24, 48, and 72 hours (data not shown). Based on the decrease in CD25 expression and reduction in Foxp3 expression, 48-or 72-hour exposure was deemed equally appropriate and superior to the shorter exposures after a single administration of LMB-2 at time 0. For the remainder of our in vitro experiments, a 48-hour harvest was used.
Specificity of LMB-2
Several immunotoxin controls were used to examine the specificity of LMB-2 cytotoxicity toward resting PBMCs. LMB-2
Asp553 is identical to LMB-2 except for a single modification (E553D) of PE38 that nearly eliminates adenosine diphosphate (ADP) ribosylation activity. Unmodified anti-Tac antibody, 20, 21 which is not fused to toxin, was also used as a control. Finally, PBMCs mechanically depleted of CD25 + cells were also used as a control to assess the nadir of Foxp3 expression. Figure 2 shows the impact of LMB-2, LMB-9, LMB-2 Asp553 , and anti-Tac (each at 100 ng/mL) on CD25 surface expression and Foxp3 expression, respectively. LMB-9 had no impact on PMBCs, suggesting that the cytotoxicity of LMB-2 was directed toward cells expressing CD25 rather than killing because of nonspecific internalization of PE38. LMB-2
Asp553 and anti-Tac had a similar impact on resting CD3 + CD4 + PBMCs, reducing CD25 expression from 19.1% to 6.2% and 6.2%, respectively, and reducing Foxp3 expression from 16.7 to 11.1 and 10.3 copies per 10 4 b-actin copies. LMB-2 had a superior depleting effect, reducing CD25 expression to 2.2% and Foxp3 expression to 7.2 copies. This experiment was performed twice with similar results. The observed reductions in CD25 and Foxp3 expression by LMB-2 Asp553 and anti-Tac suggest that blockade of the a-chain of the IL-2 receptor on resting CD4 + CD25 + cells may be detrimental to their survival, although not to the extent resulting from internalization of the toxin. Finally, the Foxp3 expression in PBMCs mechanically depleted of CD25 + cells showed even greater depletion, underscoring the partial depletion by LMB-2.
Impact of LMB-2 on CD4
+ CD25 + Regulatory T Cells
To quantify the impact of LMB-2 on resting T reg cells, large numbers of freshly isolated PBMCs were treated with or without LMB-2. After 48 hours of incubation, PBMCs were counted and mechanically sorted into CD4 + fractions by negative isolation and then into CD4 + CD25 À and CD4 + CD25 + fractions. Table 1 shows the absolute cell counts for each cell subset from 2 independently performed experiments on separate patient samples. In the first experiment, 1.5 Â 10 9 PMBCs were treated in flasks with no treatment or 100 ng/mL LMB-2 for 48 hours. The impact of LMB-2 on the 
absolute CD4
+ count and the absolute CD4 + CD25
À count was minimal (decrease of 14.4% and 1.9%, respectively). The decrease in CD4 + CD25 + cells was more profound (98.7% reduction), however. In the second experiment, starting with one fifth the total number of PBMCs compared with the first experiment, a greater reduction in was seen in the treated CD4 + fraction (47.9%), whereas an increase was observed in the absolute count of CD4 + CD25 À cells (27.4%). A similar reduction in absolute CD4 + CD25 + cell count as seen in the first experiment was observed (98.7%), however.
Using flow cytometry, surface expression of CD25 was measured on the treated PBMCs in addition to posttreated purified subsets (CD4 + cells isolated by negative selection, CD4 + cells isolated by positive selection, and CD4 + CD25 + cells). Figure 3A shows the reduction in CD25 expression on PBMCs, negatively isolated CD4 + cells, and CD4 + CD25 + cells. Figure 3B shows the reduction in CD25 expression on PBMCs as well as on negatively and positively isolated CD4 + cells from a second representative experiment. In both experiments, the reduction in CD25 expression, regardless of the method of posttreatment isolation, was between 80% and 95%.
Total RNA was isolated from the cells from these experiments, and real-time quantitative PCR was used to (Fig. 4) .
In both experiments, the reduction in Foxp3 expression in whole PBMCs was approximately 50%, whereas in CD4 + subsets, the reduction varied from 50% to 75%.
Impact of LMB-2 on Non-CD25 + Bystander Cells
The impact of LMB-2 on the surviving non-CD4 + CD25 + cells was examined using proliferation (Table 2 ) and in vitro peptide sensitization assays (Table 3) . PBMCs were harvested after 48 hours of exposure to 0 or 100 ng/mL LMB-2 and plated in 96-well plates that had been coated with anti-CD3 (1 mg/mL) at a cell concentration of 50 Â 10 3 PBMCs per well. On days 3 and 5 of cell culture, [ 3 H]-thymidine incorporation was measured (see Table 2 ). On day 3, the untreated PBMCs seemed to have a proliferative advantage compared with the treated PBMCs; however, LMB-2-treated and -untreated PBMCs had proliferated equivalently by day 5 of culture. It is unclear whether the recovery of day 5 LMB-2-treated PBMCs reflects a continued growth of non-CD25 + PBMCs or the efficient incorporation of To examine the ability of surviving PBMCs to respond to peptide stimulation, LMB-2-treated and -untreated PBMCs were cultured with relevant (Flu 58-66 ), irrelevant (gp100 280-288 (288V) ), or no soluble peptide for 10 days. The cells were then washed and plated with T2 cells pulsed with and without each peptide overnight, and IFNg secretion in the supernatant was measured (see Table 3 ). LMB-2-treated PBMCs responded to relevant peptide stimulation to a similar extent as the untreated PBMCs, suggesting that LMB-2 had no deleterious effects on the remaining CD4 + and CD8 + non-CD25 + cells.
DISCUSSION
Murine models have demonstrated that that elimination of T reg cells can augment the antitumor efficacy of the adoptive transfer of antitumor T cells. 9, 22 Conversely, the addition of T reg cells can inhibit the antitumor impact of cell transfer. 9 In humans, adoptive immunotherapy strategies that involve a nonmyeloablative lymphodepleting chemotherapy regimen before cell transfer induce an objective response rate of approximately 50% in patients with metastatic melanoma. + cells generated immunity against these tumors. 25 Further, tumor-specific T cells preferentially expanded in the lymphopenic environment after a melanoma vaccine was administered to RAG1-deficient mice reconstituted with naive T cells from normal mice. 26 The fact that simply removing T reg cells can allow effector T cells to display their innate antitumor capabilities suggests that T reg cells may paradoxically protect tumors from the host by inhibiting effector T cells from recognizing or responding to the antigenic stimulus. Because many cancer antigens are derived from nonmutated self-proteins, 27 T reg cells that may be playing a role in protection from autoimmunity may also be inhibiting antitumor responses.
The ability to surmount peripheral self-tolerance may be important to mediate in vivo antitumor responses in cancer patients. Overcoming the immunoregulatory influences of T reg cells in vivo requires clinical-grade reagents with specific targeting and elimination of T reg cells. 19 Recombinant immunotoxins and cytotoxins have been shown to deliver a cytotoxic signal targeted by the specificity of mAbs or growth factor ligands, respectively. 28 In phase I trials, immunotoxins and cytotoxins have demonstrated clinical effectiveness against malignancies expressing CD22, CD122, granulocyte macrophage colony-stimulating factor receptor (GM-CSFR), IL-13 receptor, IL-2 receptor, and CD25. 10 Because CD25, CTLA-4, and GITR represent cell surface markers of resting T reg cells to which clinical reagents can be targeted, we have initiated the evaluation of clinical-grade reagents that target these molecules on T reg cells.
We have recently treated patients with a fusion protein, Denileukin Diftitox (ONTAK), which enzymatically links the active portion of the diphtheria toxin to IL-2. 29 Because T reg cells constitutively express the highaffinity a-chain CD25, it was hypothesized that treatment with Denileukin Diftitox would specifically expose these resting CD25-expressing cells to the potent toxicities of diphtheria toxin. Thirteen patients with metastatic cancer (12 with melanoma, 1 with renal cell carcinoma) were treated with the approved low dose (9 mg/kg) or high dose (18 mg/kg) of Denileukin Diftitox without any regression of cancer or impact on T reg cells. 30 In some patients, the frequency of CD4 + CD25 + cells increased, as did normalized levels of Foxp3 expression. In addition, there was no evidence that the suppressor function of posttreatment T reg cells had decreased compared with pretreatment T reg cells. Because IL-2 is a homeostatic cytokine for T reg cells, 31 the inability of Denileukin Diftitox to eliminate T reg cells may result from the ligand triggering effect of the IL-2 portion of the fusion protein. Indeed, in previous studies, treatment of IL-2 receptorpositive T cells with IL-2-based toxin in vitro initially mimicked the stimulatory effects of IL-2 on gene transcription and DNA synthesis, yet concomitant inhibition of protein synthesis was evident. 32, 33 Based on our efforts with Denileukin Diftitox, we hypothesized that an antibody rather than a stimulating ligand may be a more suitable means to target CD25 + cells.
Whereas the anti-Tac mAb can target CD25 + alloreactive and malignant lymphocytes in vivo, the long half-life of the antibody in vivo (2-3 weeks) prevents its application in cancer immunotherapy, where developing activated antitumor T cells may also express CD25 and be destroyed. 34 In a phase I trial of LMB-2 administration, the median peak plasma level of LMB-2 was approximately 600 ng/mL, with a mean half-life of 4.5 hours at the maximum tolerated dose. 15 The short half-life of the LMB-2 immunotoxin in vivo provides the possibility of eliminating T reg cells and then administering agents such as IL-2 or cancer antigen vaccines once the immunotoxin has been cleared. 15 In the current study, we have shown that treatment with the LMB-2 immunotoxin targeting the CD25 molecule on T reg cells can selectively eliminate T reg cells in vitro without impairing the function of the remaining cells. An 8.5-fold reduction in CD25-expressing CD4
+ T cells and a 3-fold reduction in Foxp3 mRNA expression by enriched CD4 + T cells were seen after 48 hours of LMB-2 incubation compared with LMB-9 control. The disconnect between CD25 and Foxp3 reduction levels may reflect the coelimination of a small fraction of activated CD25-expressing CD4 + T cells that do not express Foxp3, although selective survival of CD25 + cells with higher Foxp3 levels is also possible. Indeed, the depletion of T reg cells is not complete based on the evaluation of CD25 and the surrogate marker Foxp3. Given that LMB-2 can reduce T reg cells in vitro, however, LBM-2 administration may provide meaningful improvement to current immunotherapeutic approaches, particularly with repeated dosing. These studies have provided the preclinical framework for the design of clinical trials to evaluate the ability of LMB-2 to eliminate T reg cells in vivo in humans.
